Advertisement
Advertisement
U.S. markets open in 7 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immunome, Inc. (IMNM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.07+0.08 (+1.60%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.99
Open5.18
Bid0.00 x 1000
Ask0.00 x 3000
Day's Range4.82 - 5.15
52 Week Range2.09 - 27.80
Volume20,437
Avg. Volume43,403
Market Cap61.486M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateAug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMNM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immunome, Inc.
    Daily – Vickers Top Insider Picks for 08/24/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • Business Wire

    Immunome Reports Second Quarter 2022 Financial Results

    EXTON, Pa., August 05, 2022--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

  • Benzinga

    Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants

    Immunome Inc (NASDAQ: IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2. Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data. The company expects topline data from Phase 1b study in 2H of 2022. IMM-BCP-01 is a three-ant

  • Business Wire

    Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

    EXTON, Pa., July 06, 2022--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 and B

Advertisement
Advertisement